Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding

Abstract

The review article discusses the safety issue of anticoagulant therapy in elderly patients with atrial fibrillation and high risk of bleeding. An evidence base is presented demonstrating the high safety of rivaroxaban in patients over 80 years of age, with a high risk of bleeding and cardiovascular complications, the presence of comorbid pathology, geriatric syndromes and chronic kidney disease (including in combination with anemia). The problem of low adherence to treatment in elderly patients and the possibility of solving it were separately considered.

Keywords

• atrial fibrillation
• elderly patient
• rivaroxaban
• safety
• high risk of bleeding